Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

51.08 +1.12 (+2.24%)
Streaming Delayed Price Updated: 3:14 PM EST, Feb 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2
...
13 14 15 16 17 18 19 20 21
...
35 36 Next >
News headline image
CRSP Stock: FDA Considers Additional Review of CRISPR Therapeutics Gene Therapy ↗
Although CRISPR Therapeutics may have a breakthrough drug on its hands, regulatory concerns hang over CRSP stock. 
Via InvestorPlace
News headline image
Questions Surround Vertex/CRISPR's Sickle Cell Gene Therapy As FDA AdComm Meeting Approaches ↗
The FDA's Cellular, Tissue, and Gene Therapies Advisory Committee will meet next  
Via Benzinga
News headline image
Vertex Pharmaceuticals: Buy at the High? ↗
Vertex shares have been flying high in recent times. 
Via The Motley Fool
News headline image
2 Fantastic Growth Stocks to Buy Hand Over Fist ↗
These stocks make great bargains today. 
Via The Motley Fool
News headline image
2 Biotech Stocks You Can Buy and Hold for the Next Decade ↗
Neither has performed well on the stock market this year. 
Via The Motley Fool
News headline image
3 No-Brainer Stocks to Buy Right Now for Less than $100 ↗
You can start with a small investment and win big over time. 
Via The Motley Fool
News headline image
CRISPR Therapeutics Stock: Bull vs. Bear ↗
Here's the scoop on one of the most widely followed gene-editing stocks on the market. 
Via The Motley Fool
News headline image
7 Biotech Stocks to Get In Now Before Investors Catch On ↗
Biotech stocks are down, but there are hidden gems among the rubble. Get in now before the broader market finds them. 
Via InvestorPlace
News headline image
Cathie Wood Is Buying These Top Growth Stocks -- and Both Could Make You Richer Over Time ↗
Wood is going all in on gene editing. 
Via The Motley Fool
News headline image
3 Gene Editing Stocks to Generate Super-Charged Gains ↗
As things progress, such techniques may be able to knock out every disease known, creating massive opportunity for gene-editing stocks. 
Via InvestorPlace
News headline image
Intellia Stumbles As It Aims For A First-Ever In CRISPR Gene Editing ↗
The company can begin a pivotal study of its treatment for cardiomyopathy. 
Via Investor's Business Daily
News headline image
Cathie Wood-Led Ark Invest Sells Over $6.5M Worth Of Tesla Stock, What's Going On? ↗
 
Via Benzinga
News headline image
Cautious Optimism For Bluebird Bio's Sickle Cell Therapy: Analyst Sees Financial Challenges ↗
Cantor Fitzgerald initiated coverage on Bluebird Bio Inc (NASDAQ: BLUE), saying sickle cell disorder (SCD) has been a hotbed of development for genetic medicines as the company's lovo-cel marches... 
Via Benzinga
News headline image
Editas Medicine Has To Navigate Sickle Cell Therapy Competition: Analyst ↗
Cantor Fitzgerald has downgraded Editas Medicine Inc (NASDAQ: EDIT) to Neutral from Overw 
Via Benzinga
News headline image
Mixed Signals For CRISPR Therapeutics, Analyst Weighs Barriers, Potential Sales For Sickle Cell Therapy ↗
Cantor Fitzgerald has downgraded CRISPR Therapeutics AG (NASDAQ: CRSP) to Neutral from Ov 
Via Benzinga
News headline image
This Cathie Wood Stock Is Set to Soar 100%, Says Wall Street ↗
This Wood favorite is heading for a big moment. 
Via The Motley Fool
News headline image
2 Growth Stocks That Could Double Your Money, According to Wall Street ↗
Find out why investment bank analysts are pounding the table on these stocks. 
Via The Motley Fool
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For October 17, 2023 ↗
 
Via Benzinga
News headline image
2 Growth Stocks That Could Deliver Parabolic Returns in Under 5 Years ↗
These two gene-editing stocks could be diamonds in the rough. 
Via The Motley Fool
News headline image
Cathie Wood's Ark Invest Sells $9.8M Worth Of Tesla Shares — Second Day Of Selling EV Giant In A Row ↗
 
Via Benzinga
News headline image
Cathie Wood's Ark Invest Keeps On Cutting Tesla Holdings, Sells More Than $8M Worth Of EV Maker's Shares ↗
 
Via Benzinga
News headline image
Cathie Wood Is Buying CRISPR Therapeutics Ahead of This Big Event. Should You? ↗
Wood has outperformed the market so far this year. 
Via The Motley Fool
News headline image
Cathie Wood Goes Shopping For Stock of Jack Dorsey's Block — Ark Invest Bolsters Portfolio With Archer Aviation, CRISPR Shares ↗
 
Via Benzinga
News headline image
3 No-Brainer Growth Stocks to Buy in October ↗
The time is right to invest in these great stocks. 
Via The Motley Fool
News headline image
2 Growth Stocks That Can Rocket 98% to 108% Higher, According to Wall Street ↗
The analysts who follow these stocks have some big expectations for the year ahead. 
Via The Motley Fool
News headline image
Cathie Wood's Ark Invest Sells Over $25M Worth Of Tesla Shares Amid Boost In Price ↗
 
Via Benzinga
News headline image
Biotechnology Breakthroughs: 3 Biotech Stocks That Could Make Early Investors Rich ↗
Are you looking to invest in biotechnology breakthroughs? Here are three biotech stocks that could make early investors rich. 
Via InvestorPlace
News headline image
Cathie Wood Is Buying This Growth Stock Hand Over Fist Lately. Should You Follow Her Lead? ↗
The Internet's most famous innovation-focused investor is excited about this company's innovative approach to editing the human genome. 
Via The Motley Fool
News headline image
2 Top Biotech Stocks to Buy in October ↗
Growth catalysts lie ahead for both of these players. 
Via The Motley Fool
News headline image
Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics ↗
The better of the pair should be able to beat Bluebird Bio. 
Via The Motley Fool
< Previous 1 2
...
13 14 15 16 17 18 19 20 21
...
35 36 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.